Efficacy and HCC development after DAA therapy for patients with chronic hepatitis C: a single center retrospective cohort study

Abstract

Aim: The development of hepatocellular carcinoma (HCC) is reduced after interferon based treatment in patients with chronic hepatitis C (CHC). A new therapy using direct-acting antiviral agents (DAA) has been widely applied since 2014 for CHC. The purpose of this study is to investigate the efficacy, safety and development of HCC after DAA treatment.

Methods: The authors enrolled 33 consecutive patients who were treated with DAA for CHC at the hospital between January 2015 and March 2016. The laboratory data were collected at the start and 24 weeks after DAA therapy.

Results: The authors analyzed 33 patients (18 male, 15 female, mean age of 68-year-old). The hepatic C virus genotypes were type 1 (27 patients) and type 2 (6 patients). The number of patients treated with sofosbuvir (SOF) + ledipasvir, daclatasvir + asunaprevir and SOF + ribavirin was 14, 13 and 6, respectively. The sustained virological response (SVR24) rate was 100%. Aspartate aminotransferase, alanine aminotransferase and FIB4-index were significantly decreased after SVR24. Adverse effects were observed in 9 patients (anemia, 5; liver function test disorder, 2; sarcoidosis, 1; pruritus, 1). With regard to HCC development, one elderly patient (3.0%) had multiple HCC recurrence after SVR24.

Conclusion: DAA therapy achieved a high SVR24 rate with a good serological response. However, one patient had multiple HCC recurrence. These findings indicate that careful follow-up may be essential after DAA therapy.

Keywords

Chronic hepatitis C / direct-acting antiviral therapy / development of hepatocellular carcinoma / sarcoidosis

References

[1] Fried MW,Reddy KR,Marinos G,Häussinger D,Carosi G,Craxi A,Hoffman J.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection..N Engl J Med2002;347:975-82

[2] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies..Ann Intern Med2013;158:329-37

[3] Shiratori Y,Moriyama M,Arakawa Y,Kuroki T,Sata M,Fujiyama S,Omata M.Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy..Ann Intern Med2000;132:517-24

[4] Cammà C,Schepis F,Zeuzem S,Marcellin P,Alberti A.Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data..Hepatology2004;39:333-42

[5] Poynard T,Manns M,Albrecht J.Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin..Hepatology2003;38:481-92

[6] Heathcote EJ,Cooksley WG,Lee SS,Reindollar R,Wright TL,Hoffman J.Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis..N Engl J Med2000;343:1673-80

[7] Kumada H,Ikeda K,Karino Y,Kawakami Y,Yamamoto K,Izumi N,Takehara T,Sata M,Eley T,Damokosh A,Hughes E.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection..Hepatology2014;59:2083-91 PMCID:PMC4315868

[8] Soota K.Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection..World J Gastroenterol2014;20:16184-90 PMCID:PMC4239506

[9] Kim SK,Imoto S,Hayashi Y.Sudden-onset sarcoidosis with severe dyspnea developing during pegylated interferon and ribavirin combination therapy for chronic hepatitis C..Turk J Gastroenterol2017;28:75-6

[10] Buss G,Spring P,Gilliet M.Two cases of interferon-alpha-induced sarcoidosis Koebnerized along venous drainage lines: new pathogenic insights and review of the literature of interferon-induced sarcoidosis..Dermatology2013;226:289-97

[11] Joshita S,Yazaki Y,Nakamura Y,Noami S,Yagi H,Yamazaki A,Umemura T,Tanaka E.Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy..Hepatol Res2013;43:801-7

[12] Hung CH,Lu SN,Hu TH,Chen CH,Changchien CS.Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis..J Viral Hepat2006;13:409-14

[13] Velosa J,Marinho R,Glória H.Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis..Dig Dis Sci2011;56:1853-61

[14] Floreani A,Rizzotto ER,Baldovin T.Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis..J Clin Gastroenterol2008;42:734-7

[15] Bruno S,Colombo M,Benvegnù L,Ascione A,Piccinino F,Mangia A,Persico M,Almasio PL.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study..Hepatology2007;45:579-87

[16] Hisaka T,Ogasawara S,Nishida N,Kojiro S,Kojiro M.Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo..J Hepatol2004;41:782-9

[17] Izumi N,Kurosaki M,Kawai T,Okamura Y,Yokosuka O,Toyoda J,Tanaka E,Adachi H,Kudo M,Hiasa Y,Yatsuhashi H,Kumada H.Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study..J Gastroenterol2013;48:382-90 PMCID:PMC3618412

[18] Cheung MC,Hudson BE,McLauchlan J,Brown A,MacDonald DC,Foster GR,HCV Research UK..Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis..J Hepatol2016;65:741-7

[19] ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts)..Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts..J Hepatol2016;65:734-40

[20] Conti F,Scuteri A,Bolondi L,Foschi FG,Mazzella G,Andreone P.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[21] Reig M,Perelló C,Ribeiro A,Díaz A,Darnell A,Sangro B,Forns X.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[22] Kobayashi M,Fujiyama S,Sezaki H,Akuta N,Saitoh S,Ikeda K.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection..J Med Virol2017;89:476-83